1

Lipid storm within the lungs of severe COVID-19 patients: Extensive levels of cyclooxygenase and lipoxygenase-derived inflammatory metabolites *Anne-Sophie Archambault^{1,2}, *Younes Zaid^{3,4}, Volatiana Rakotoarivelo^{1,2}, Étienne Doré^{5,6}, Isabelle Dubuc⁵, Cyril Martin^{1,2}, Youssef Amar⁷, Amine Cheikh⁴, Hakima Fares⁴, Amine El Hassani⁴, Youssef Tijani⁸, Michel Laviolette¹, Éric Boilard^{5,6,9}, [#]Louis Flamand^{5,9} and [#]Nicolas Flamand^{1,2}. *ASA and YZ equally contributed to this work. [#]LF and NF equally contributed to this work ¹Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec, Faculté de médecine, Département de médecine, Université Laval, Ouébec City, OC, Canada ²Canada Research Excellence Chair in the Microbiome-Endocannabinoidome Axis in Metabolic Health, Université Laval, Ouébec, OC, Canada. ³Biology Department, Faculty of Sciences, Mohammed V University, Rabat, Morocco ⁴Cheikh Zaïd Hospital, Abulcasis University of Health Sciences, Rabat, Morocco ⁵Centre de Recherche du Centre Hospitalier Universitaire de Québec- Université Laval, Canada; ⁶Centre de Recherche Arthrite, Université Laval, Québec, Canada ⁷Moroccan Foundation for Advanced Science, Innovation & Research (MAScIR), Rabat, Morocco ⁸Faculty of Medicine, Mohammed VI University of Health Sciences, Casablanca, Morocco ⁹Département de microbiologie-infectiologie et d'immunologie, Université Laval, QC, Canada **Corresponding authors:**

26	Nicolas Flamand, PhD	Louis Flamand, PhD
27	Centre de recherche de l'IUCPQ	Centre de recherche du CHU-CHUL
28	2725 chemin Ste-Foy, Office A3140	2705 Laurier boulevard, Office T1-64
29	Québec City, QC G1V 4G5, Canada	Québec City, QC G1V 4G2, Canada
30	Tel: 1-418-656-8711 ext.3733	Tel: 1-418-525-4444 ext.46164
31	Email: <u>Nicolas.Flamand@criucpq.ulaval.ca</u>	Email: Louis.Flamand@crchudequebec.ulaval.ca
32		

33

1 2

3

4

5

6

7

8 9

10

11 12

13

14 15

16

17

18

19

20

21 22

23

24

25

34 Funding: This work was supported by the Cheikh Zaid Foundation awarded to YZ and grants from the 35 Canadian New Frontier Research Fund (NFRN-2019-00004) awarded to LF (PI), EB (co-PI) and NF (co-

PI) and the Natural Sciences and Engineering Research Council of Canada awarded to NF. ASA received 36

37 a doctoral award from the Canadian Institutes of Health Research. ED and EB are respectfully recipient

38 of doctoral and senior awards from the Fonds de Recherche du Québec en Santé (FROS).

2

39 ABSTRACT

40

BACKGROUND. Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) is the infectious agent responsible for Coronavirus disease 2019 (COVID-19). While SARS-CoV-2 infections are often benign, there are also severe COVID-19 cases, characterized by severe bilobar pneumonia that can decompensate to an acute respiratory distress syndrome, notably characterized by increased inflammation and a cytokine storm. While there is no cure against severe COVID-19 cases, some treatments significantly decrease the severity of the disease, notably aspirin and dexamethasone, which both directly or indirectly target the biosynthesis (and effects) of numerous bioactive lipids.

48

49 OBJECTIVE. Our working hypothesis was that severe COVID-19 cases necessitating mechanical 50 ventilation were characterized by increased bioactive lipid levels modulating lung inflammation. We thus 51 quantitated several lung bioactive lipids using liquid chromatography combined to tandem mass 52 spectrometry.

53

54 **RESULTS.** We performed an exhaustive assessment of the lipid content of bronchoalveolar lavages 55 from 25 healthy controls and 33 COVID-19 patients necessitating mechanical ventilation. Severe 56 COVID-19 patients were characterized by increased fatty acid levels as well as an accompanying 57 inflammatory lipid storm. As such, most quantified bioactive lipids were heavily increased. There was a 58 predominance of cyclooxygenase metabolites, notably $TXB_2 \gg PGE_2 \sim 12$ -HHTrE > PGD₂. 59 Leukotrienes were also increased, notably LTB₄, 20-COOH-LTB₄, LTE₄, and eoxin E₄. 15-lipoxygenase 60 metabolites derived from linoleic, arachidonic, eicosapentaenoic and docosahexaenoic acids were also increased. Finally, yet importantly, specialized pro-resolving mediators, notably lipoxin A4 and the D-61 62 series resolvins, were also found at important levels, underscoring that the lipid storm occurring in severe 63 SARS-CoV-2 infections involves pro- and anti-inflammatory lipids.

64

65 **CONCLUSIONS.** Our data unmask the important lipid storm occurring in the lungs of patients afflicted 66 with severe COVID-19. We discuss which clinically available drugs could be helpful at modulating the 67 lipidome we observed in the hope of minimizing the deleterious effects of pro-inflammatory lipids and 68 enhancing the effects of anti-inflammatory and/or pro-resolving lipids.

3

70 Abbreviations

2-AG, 2-arachidonoyl-glycerol; AA, arachidonic acid; AEA, *N*-arachidonoyl-ethanolamine; ALT,
 alanine transaminase; AST, aspartate transaminase; BAL, bronchoalveolar lavage; COVID-19,
 coronavirus disease 2019; COX, cyclooxygenase; CRP, C-reactive protein; DGLA, dihomo-γ-linolenic

- 74 acid; DHA, docosahexaenoic acid; DPA, docosapentaenoic acid; EPA, eicosapentaenoic acid; EX,
- rs eoxin; HETE, hydroxyeicosatetraenoic acid; ICU, intensive care unit; IL, interleukin; LA, linoleic acid;
- 76 LDH, lactate dehydrogenase; LOX, lipoxygenase; LT, leukotriene; PG, prostaglandin; Rv, resolvin;
- 77 SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SPM, specialized proresolving
- 78 mediator; TX, thromboxane.
- 79

4

80 INTRODUCTION

81 Coronavirus disease 2019 (COVID-19) is an infectious disease caused by the Severe Acute Respiratory 82 Syndrome coronavirus 2 (SARS-CoV-2) (1). The clinical manifestations of the disease are often mild 83 but severe cases can lead to bilobar pneumonia with hyperactivation of the inflammatory cascade and 84 progression to acute respiratory distress syndrome (ARDS), necessitating mechanical ventilation (2, 3). 85 SARS-CoV-2 spreads predominantly from respiratory droplets of infected individuals to mucosal 86 epithelial cells in the upper airways and oral cavity (4). It infects cells *via* its homotrimeric spike protein 87 binding to host-cell expressing angiotensin-converting enzyme-2 (ACE2) receptor in a protease-88 dependent manner (5).

89

90 Autopsies from severe COVID-19 patients unmasked a heterogeneous disease that can be characterized 91 by diffuse alveolar damage, endothelial damage, thrombosis of small and medium vessels, pulmonary embolism, and inflammatory cell infiltration, sometimes more lymphocytic, sometimes more 92 93 granulocytic (3, 6-8). An uncontrolled systemic inflammatory response known as the cytokine storm also 94 occurs. This cytokine storm, which is the consequence of an important release of pro-inflammatory 95 cytokines, such as tumor necrosis factor- α , interleukin (IL)-1 β , IL-6, IL-7 and granulocyte-colony 96 stimulating factor, is suggested as an important contributor of SARS-CoV-2 lethality (8, 9). However, 97 the heterogeneity of the disease indicates that, aside cytokines (and chemokines), other immunological 98 effectors contribute to the sustained inflammatory responses observed in the most severe forms of 99 COVID-19.

100

Among the numerous soluble effectors involved in the infectious/inflammatory response, bioactive lipids such as eicosanoids likely promote their fair share of deleterious effects, notably by enhancing leukocyte recruitment and activation, by participating in the exudate formation and by stimulating platelet aggregation and thrombus formation. In contrast, specialized pro-resolving mediators (SPMs), which mainly consist of docosanoids, could dampen the inflammatory response and even promote its resolution (10). While therapeutic approaches targeting the biosynthesis or effects of inflammatory lipids are readily available, the levels of those lipids in the lungs during severe COVID-19 remain unknown.

108

Herein, we performed a detailed lipidomic analysis of bronchoalveolar lavage (BAL) fluids from healthy
volunteers and severe COVID-19 patients. We provide evidence that severe COVID-19 patients are

111 characterized by robust levels of lipids arising from the cyclooxygenase (COX) and lipoxygenase (LOX)

- 112 pathways as well increased SPM levels. Our study further highlights that few associations exist between
- 113 clinical parameters and bioactive lipids present in the primary site of disease, the lungs.

114 MATERIAL AND METHODS

115

116 Materials

117 All lipids were obtained from Cayman Chemical (Ann Arbor, MI, USA) unless indicated otherwise.

- 118 DMSO and C17:1-LPA were purchased from Sigma-Aldrich (St-Louis, MO, USA). DMSO, ammonium
- 119 acetate, acetic acid, LC-MS-grade MeOH, MeCN and H₂O were purchased from Fisher Scientific
- 120 (Ottawa, Canada). Cytokine/chemokine bead arrays were purchased from Becton Dickinson (BD).
- 121

122 Ethics

123 This study was approved by the Local Ethics Committee of Cheikh Zaid Hospital (Project: 124 CEFCZ/PR/2020- PR04), Rabat, Morocco and complies with the Declaration of Helsinki and all subjects 125 signed a consent form. The analysis of bioactive lipids in the BAL of healthy donors and severe COVID-126 19 patients was approved by the Comité d'éthique de la recherche de l'Institut universitaire de cardiologie 127 et de pneumologie de Québec – Université Laval and the Comité d'éthique de la recherche du CHU de 128 Québec-Université Laval.

129

130 Clinical criteria for subject selection. Non-smoking healthy subjects taking no other medication than anovulants, without any documented acute or chronic inflammatory disease and without recent (8 weeks) 131 airway infection were recruited for bronchoalveolar lavages at Institut universitaire de cardiologie et 132 133 pneumologie de Québec (Québec City, Canada). Only BALs in which the cell content in alveolar 134 macrophages was greater than 95%, with lymphocytes as the other main cell type, were kept for further 135 analyses. Severe COVID-19 patients were enrolled based on the inclusion criteria for intubation and the need of mechanical ventilation support at Cheikh Zaid Hospital (Rabat, Morocco). Following intubation 136 137 and the initiation of mechanical ventilation, blood sampling was done to assess the clinical variables 138 shown in Table 1. Patients were ventilated in the prone decubitus position with a tidal volume of 6 ml/kg 139 and a PEEP varying between 8 - 14 cm H₂O. The FiO₂ was adjusted between 0.6 - 1.0 to obtain a SpO₂ 140 ≥92%.

141

Bronchoalveolar lavages. BAL fluids from healthy volunteers were obtained as follows: One 50 ml bolus of sterile 0.9% saline was injected in a sub-segmental bronchi of the right middle lobe. The obtained lavages were centrifuged ($350 \times g$, 10 minutes) to pellet cells and the supernatants were immediately frozen (-80° Celsius) until further processing. A 5 ml aliquot of the samples was thawed then reduced to ~500 µl using a stream of nitrogen. BAL fluids from severe COVID-19 patients were obtained less than

7

147 2 hrs following intubation and as follows: a total of 100 ml of sterile 0.9% saline (2 boli of 50 ml) was 148 injected in a sub-segmental bronchi of the right middle lobe. The obtained lavages were pooled and 149 centrifuged ($320 \times g$, 15 minutes) to pellet cells. Supernatants were next concentrated as for the BALs of 150 healthy donors using a stream of nitrogen and immediately frozen (-80° Celsius) until further processing.

- 151 All of the evaporated samples were processed for LC-MS/MS analysis as described below.
- 152

153 LC-MS/MS analyses. Samples (500 µl) were denatured by adding 500 µl of LC-MS grade MeOH 154 containing the internal standards then warmed at 60° Celsius for 30 minutes to inactivate (or not) SARS-155 CoV-2. Samples were then denatured overnight (-20° Celsius). The morning after, samples were warmed 156 to room temperature and centrifuged at $10,000 \times g$ to remove the denaturated proteins. The obtained 157 supernatants were diluted with water containing 0.01% acetic acid to obtain a MeOH concentration of 158 10%, then acidified to pH 3 with acetic acid. Lipids were extracted by solid phase extraction (SPE) using 159 Strata-X cartridges (Polymeric Reversed Phase, 60 mg/1 ml, Phenomenex, Torrance, CA, USA) as 160 described before (11). In brief, columns were preconditioned with 2 ml MeOH containing 0.01% acetic 161 acid followed by 2 ml LC-MS grade H₂O containing 0.01% acetic acid. After sample loading, the columns were washed with 2 ml LC-MS grade H₂O containing 0.01% acetic acid. Lipids were then eluted 162 163 from the cartridges with 1 ml MeOH containing 0.01% acetic acid. Eluates were dried under a stream of 164 nitrogen and reconstituted with 25 μ l of solvent A (H₂O + 1 mM NH₄ + 0.05% acetic acid) and 25 μ l of 165 solvent B (MeCN/H₂O, 95/5, v/v + 1 mM NH₄ + 0.05% acetic acid). A volume of 40 µl of the resulting mixture was injected onto a RP-HPLC column (Kinetex C8, 150×2.1 mm, 2.6μ m, Phenomenex). 166 167 Samples were eluted at a flow rate of 400 µl/min with a linear gradient of 10% solvent B that increased 168 to 35% in 2 min, up to 75% in 10 min, from 75% to 95% in 0.1 min, and held at 98% for 5 min before 169 re-equilibration to 10% solvent B for 2 min. The HPLC system was directly interfaced into the 170 electrospray source of a Shimadzu 8050 triple quadrupole mass spectrometer and mass spectrometric 171 analyses were performed in the positive (+) or the negative (-) ion mode using multiple reaction 172 monitoring for the specific mass transitions of each lipid (Table 2). Quantification of each compound was done using internal standards and calibration curves that were extracted by solid-phase extraction as 173 174 described above.

175

176 Statistical analysis

Statistical analyses were done using the GraphPad Prism 9 software. P values < 0.05 were considered
significant.

8

180 **RESULTS**

While the circulating (plasmatic) cytokines' profile observed in severe COVID-19 patients is relatively 181 182 well-defined (8, 12-14), a much more limited number of studies characterizing the cytokine storm in the 183 lungs of severe COVID-19 patients were available (13, 15, 16). In fact, to the best of our knowledge, no 184 study simultaneously quantitated numerous soluble mediators in BAL fluids. We thus performed their 185 lipidomic analysis in order to define whether an inflammatory lipid storm was present in the lungs of 186 severe COVID-19 patients. Samples were compared to those obtained from healthy subjects. As a 187 starting point, we investigated eicosanoids derived from the cyclooxygenase (COX) pathway. Our 188 working hypothesis was that some COX metabolites would be increased, considering that IL-1ß levels 189 are elevated in the BALs of some COVID-19 patients (16) and that IL-1ß is a potent inducer of 190 cyclooxygenase (COX)-2 expression (17-19). The only COX metabolites that were detected in the BALs 191 of healthy subjects were PGD₂ (16 donors out of 25) and 12-HHTrE (2 donors out of 25). In contrast, 192 BALs from severe COVID-19 patients had a significant increase of all COX metabolites investigated 193 (figure 1). Most samples had detectable levels of PGD₂ (27 of 33 donors) and the PGI₂ metabolite 6-194 keto-PGF_{1a} (16 of 33 donors), while all samples contained PGF_{2a}, important levels of PGE₂, the inactive 195 TXA₂ metabolite TXB₂, and the thromboxane synthase metabolite 12-HHTrE (figure 1A). Although 196 there was a significant increase in all metabolites, the most increased COX-derived metabolites were 197 $TXB_2 >> PGE_2 \sim 12$ -HHTrE > PGD₂. We next addressed if the different COX metabolites correlated 198 with each other. The levels of TXB₂ strongly correlated with those of 12-HHTrE, PGD₂, PGE₂ and PGF_{2a} 199 (figure 1B-E). Of note, few correlations were found between COX metabolites and the clinical 200 parameters shown in Table1. To that end, $PGF_{2\alpha}$ and 12-HHTrE weakly but significantly correlated 201 negatively with AST (figure 7),

202

203 Leukotrienes are also potent bioactive lipids previously documented to regulate the inflammatory 204 responses in the airway/lung in diseases, notably ARDS (20, 21). As such, their involvement in the 205 pathogenesis of COVID-19 has recently been postulated even though their levels were unknown (22). 206 We thus quantitated the levels of leukotrienes derived from the 5-lipoxygenase pathway as well as those 207 derived from the 15-lipoxygenase pathway, the 14,15-leukotrienes, which are now classified as eoxins 208 (23). Leukotrienes were not detected in the BAL fluids of healthy volunteers, with the exception of LTB₄, 209 which was detected in 4 of 25 healthy subjects. In contrast, COVID-19 patients were characterized by 210 increased levels of LTB4 and its CYP4F3A metabolite 20-COOH-LTB4 (figure 2A) as well as other 211 minor metabolites (20-OH-LTB4 and 12-oxo-LTB4). Of note, the levels of LTB4 found in the BAL fluids of severe COVID-19 patients are comparable to those found in BAL fluids of ARDS patients (16). As 212

213 expected, there was a strong correlation between the levels of LTB₄ and those of 20-COOH-LTB₄ (figure 214 **2B**). Importantly, the ratio between the sum of 20-OH- and 20-COOH-LTB₄ to LTB₄ ((20-OH- \pm 20-215 COOH-LTB₄/LTB₄) was 2.843 +/- 0.532 (mean +/- SEM), indicating an increased omega oxidation of 216 LTB₄. The levels of LTB₄ strongly correlated with those of TXB₂ (figure 2C). The cysteinyl-leukotrienes 217 LTE₄ and EXE₄ were also found in most severe COVID-19 patients (figure 2D). Surprisingly, the levels 218 of EXE₄ trended to be higher than those of LTE₄. Furthermore, there was a trend toward a negative 219 correlation between LTE₄ and EXE₄ levels although it did not reach statistical significance (figure 2E). 220 This suggests that some COVID-19 patients are more prone to biosynthesize the 15-lipoxygnease-221 derived EXC₄ while others are more prone to biosynthesize the 5-lipoxygenase-derived LTC₄. Of note, 222 LTB₄ levels correlated with those of EXE₄ but not with those of LTE₄ (figure 2F,G). Again, a limited 223 number of correlations between the different leukotrienes and the clinical parameters from Table 1 were 224 found (figure 7), supporting the concept that the levels of leukotrienes in the lungs are not reflected in 225 the blood by the most recognized COVID-19-related biomarkers.

226

227 The prostaglandins and leukotrienes data (figures 1 and 2) support the idea that an increase in both 228 arachidonic acid (AA) release and metabolism occurs in severe COVID-19 patients. As such, we 229 investigated the levels of some fatty acids, which are the precursors of oxidized linoleic acid (LA) 230 mediators (OXLAMs), eicosanoids and docosanoids. To that end, the levels of LA, AA, 231 docosapentaenoic acid n-3 (DPAn-3) and docosahexaenoic acid (DHA) were all significantly increased 232 in the BALs of severe COVID-19 patients. In contrast, the levels of eicosapentaenoic acid (EPA) did not 233 change (figure 3). Of note, all tested BAL fatty acids negatively correlated with AST and ALT but 234 positively correlated with the circulating platelet-to-lymphocyte ratio (figure 7).

235

The increased fatty acid levels (figure 3) and the increased in the 15-lipoxygenase-derived eoxins (figure 236 237 2D) led us to investigate if other fatty acid-related biosynthetic pathways were also enhanced in SARS-238 CoV-2-infected patients. To that end, we also quantitated additional AA-derived metabolites derived 239 from the 12- and 15-lipoxygenases. The levels of 12-HETE and 15-HETE were also significantly 240 increased in the BAL fluids of severe COVID-19 patients, although not to the same extent than the 5-241 lipoxygenase metabolite 5-HETE (figure 4A), indicating that AA metabolism via the 15-lipoxygenase 242 (and possibly the 12-lipoxygenase) pathway is increased. In addition to AA, the 15-lipoxygenase 243 pathway can metabolize numerous polyunsaturated fatty acids having a 1Z,4Z-pentadiene motif near 244 their omega end, notably LA, EPA, DPAn-3 and DHA. We thus also assessed the levels of their most 245 documented 15-lipoxygenase metabolites and found significant increases in 13-HODE (derived from

10

246 LA), 15-HETrE (derived from dihomo-y-linolenic acid, DGLA), 12-, 15-, and 18-HEPE, 17-HDPA(n-247 3) as well as 14- and 17-HDHA (figure 4B,C). Dual lipoxygenases metabolites from AA were also 248 significantly increased (figure 4D). Of note, the levels of 15-HETE strongly correlated with those of 13-249 HODE (figure 4E) supporting an increased 15-lipoxygenase activity in the lungs of severe COVID-19 250 patients. Furthermore, 15-HETE levels also correlated with those of TXB_2 (figure 4F). Finally yet 251 importantly, we also detected significant increases in 9-HODE, 8-HETE, and 11-HETE, which arise from 252 the non-enzymatic oxidation of LA and AA, pointing to an increased oxidative bust in the lungs of severe 253 COVID-19 patients (figure 4A,B).

254

255 14- and 17-HDHA, which are increased in the BALs of severe COVID-19 patients (figure 4C), are often 256 regarded as good indicators of D-series resolvin and maresin levels, which are part of the ever-expanding 257 class of specialized pro-resolving mediators (SPMs). SPMs are usually more complicated to quantitate 258 due to their very low concentrations (10). Given their documented pro-resolving actions and anti-259 microbial activities, SPMs were recently postulated as being a potential approach for diminishing the 260 inflammatory burden of COVID-19 (24). We thus investigated the levels of some commercially available 261 SPMs. All SPMs were below detection limit in the BAL samples of healthy volunteers we analyzed. In 262 contrast, most investigated SPMs, aside from RvD3, were detected in the BAL fluids of severe COVID-263 19 patients. LXA₄ was the most prominent one, followed by RvD4, RvD5, RvD2, RVD1 and PDX 264 (figure 5A). RvD5 levels correlated with those of RvD4 (figure 5B) but not those of DHA (figure 5C) indicating that the same patients are responsible for the increased D-series resolvins, which is mostly due 265 266 to increased 15-lipoxygenase activity rather than an increase in DHA availability. The levels of RvD5 267 also correlated with those of TXB_2 (figure 5D). Again, there was no correlation between RvD5 with the 268 clinical parameters from table 1. Unsurprisingly, the levels of LXA₄ correlated with those of 5-HETE 269 and 15-HETE (figure 5E,F), given that LXA₄ biosynthesis requires both the 5- and the 15-lipoxygenase 270 pathways. As for RvD5, the levels of LXA4 also correlated with those of TXB2 and the other 271 prostaglandins (figure 6). Despite our good sensitivity (see table 2), we did not detect the presence or 272 RvE1, Maresin-1 and -2.

273

When assessing the lipidome for which we could quantitate a given lipid mediator in at least 50% of severe COVID-19 patients, we can appreciate that most lipids consistently correlated with each other with few exceptions (**figure 6**). Indeed, Fatty acids levels were not a key determinant for the levels of their metabolites, indicating that downstream enzymes (cyclooxygenases, lipoxygenases) are likely more important in that respect. Furthermore, and in agreement with their almost significant negative

- association (figure 2E), EXE₄ and LTE₄ correlated with different bioactive lipid subsets, LTE₄ positively
- 280 correlating with fatty acid and 15-HETrE levels while EXE4 mostly correlating with other 15-
- 281 lipoxygenase metabolites.

282 **DISCUSSION**

283

Bioactive lipids are recognized pharmaceutical targets for the treatment of numerous inflammatory diseases and lipid modulators have been utilized as such, in the last fifty years, with great success. It was thus imperative, at least to us, to define whether bioactive lipid levels were modulated in the context of severe COVID-19.

288

Herein, we provide clear evidences that the BALs of severe COVID-19 patients contain large amounts of bioactive lipids, which likely participate in the deleterious inflammatory response found in severe cases. More specifically, our data indicate that the BALs of severe COVID-19 patients are characterized by **1**) an increase in COX metabolites, notably the TXA₂ metabolite TXB₂; **2**) an increase in LTB₄ and its metabolites; **3**) an increase in CysLT metabolites; **4**) an increase of 15-lipoxygenases metabolites derived from LA, AA, EPA, DPA and DHA; **5**) an increase in SPMs derived from AA and DHA; and **6**) a limited number of correlations between BAL lipids *vs*. blood markers and/or clinical parameters.

296

297 Cyclooxygenase metabolites were heavily increased in the BALs of severe COVID-19 patients (figure 298 1). This was somewhat expected, notably because of the increased levels of IL-1 β described before (16), 299 the latter being a good COX-2 inducer. In the lungs, COX metabolites play multiple roles. TXA2 300 promotes bronchoconstriction and activate inflammatory cells and platelets, which might be consistent 301 with the reported enhanced platelet activation and increased thrombosis in COVID-19 (14, 25, 26). On 302 the other hand, PGD₂ acting via the DP₂ receptor promotes the recruitment and activation of eosinophils, 303 basophils, mastocytes and innate lymphoid cells (27-30). In contrast, PGE_2 is usually regarded as anti-304 inflammatory in the lungs, notably by downregulating the pro-inflammatory functions of myeloid leukocytes such as neutrophils and macrophages, notably by activating the EP₂ and EP₄ receptors, 305 306 ultimately leading to increased cyclic AMP levels (31). Therapies targeting the prostaglandin pathway 307 are numerous and usually effective at controlling inflammation. Dexamethasone, a steroid improving 308 COVID-19 symptoms and diminishing mortality (32-34), limits COX-2 expression (35-37) and might thus improve COVID-19 severity, at least in part, by diminishing the biosynthesis of prostaglandins and 309 310 possibly TXA₂. Furthermore, nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin and 311 ibuprofen are recognized inhibitor of cyclooxygenase activity. Early at the beginning of the pandemic, it 312 was postulated that NSAIDs could worsen the severity of COVID-19 (38). However, a Danish study 313 indicated that ibuprofen was not linked to severe adverse outcome (39). Furthermore, aspirin was recently 314 shown to significantly diminish ICU admissions and the need of mechanical ventilation in an

13

315 observational, retrospective study (40). Altogether, our data, combined with the recent studies on their 316 safety in a context of COVID-19, support the hypothesis that dexamethasone and NSAIDs might 317 diminish the inflammatory status of severe COVID-19 patients by diminishing the 318 prostaglandins/thromboxane storm in the lungs. While TXA₂ and PGD₂ might have deleterious effects 319 in the lungs, PGE₂ and PGI₂ might have the opposite effect, notably by inhibiting leukocyte functions 320 (PGE₂) and/or promoting the vasodilation of the microvasculature (PGI₂). To that end, testing whether 321 blocking the deleterious effects of PGD₂ and TXA₂ with the dual DP₂/TP antagonist Ramotraban might 322 be beneficial in this particular context, as proposed recently (41).

323

Prostaglandins and TXA₂, as assessed by quantitating TXB₂ levels, were not the only eicosanoids that 324 325 were increased in the BALs of severe COVID-19 patients. Indeed, leukotrienes were also increased, 326 notably LTB₄, LTE₄, and EXE₄ (figure 2). This indicates that in addition of the deleterious effects that 327 some COX metabolites might have, those linked to LTB₄ and CysLTs might also impair lung functions and participate in the inflammatory burden in the lungs of severe COVID-19 patients (22). While LTB4 328 329 has previously been shown to stimulate host defense (41), notably during viral infections, the 330 ω -LTB₄/LTB₄ ratio of 2.84 we observed is more reminiscent of what is found in cystic fibrosis and 331 severely burned patients, two conditions in which infections are not well controlled (42-45). 332 Conceptually, this might diminish the effectiveness of LTB₄ at promoting its host-defense related 333 functions, as we recently published (46). Interestingly, there was a trend toward an inverse correlation 334 between LTE₄ and EXE₄, indicating that these cysteinyl-LTs are likely coming from different cellular sources. This was supported by the differential and significant correlations between the different lipids 335 we observed, LTE₄ and EXE₄ differentially correlating with distinct lipids (figure 6). To that end, EXE₄ 336 337 levels in the BALs positively and significantly correlated with blood eosinophils counts. While there was 338 a strong trend between EXE_4 and BAL eosinophils counts the latter correlation had a p value of 0.0536. 339 Altogether, this suggests that the presence and/or biosynthesis of eoxins is, in part, linked to eosinophils. 340 A therapeutic approach to target LTs from the 5-lipoxygenase pathway could be the use of Zileuton, 341 which is commercially available for the management of asthma and has a good safety profile (47).

342

Another pharmaceutical approach that could simultaneously diminish the levels of COX and 5-lipoxygenase-derived eicosanoids could be the use of phosphodiesterase 4 inhibitors such as Roflumilast. While there is no evidence of phosphodiesterase 4 inhibitors' efficacy in the management of SARS-CoV-2-infected people (48), they might diminish inflammation by preventing the degradation of cyclic AMP, increasing intracellular cAMP concentrations and decreasing the release of AA, the

14

precursor of prostaglandins and leukotrienes. Furthermore, cAMP-elevating agents such as adenosine and PGE₂ are recognized anti-inflammatory autacoids that inhibit numerous leukocyte functions such as eicosanoid biosynthesis, oxidative burst, calcium mobilization and migration (49-53). While phosphodiesterase 4 inhibitors might diminish the levels of PGE₂ by diminishing AA levels, they would nonetheless amplify the inhibitory effects of the remaining PGE₂, as recently demonstrated *in cellulo* (54).

354

355 While it is largely accepted that the group IVA cytosolic phospholipase A₂ mediates most of AA release 356 in activated human leukocytes (e.g. in (55)), the increased levels of LA, EPA and DHA support the idea 357 that other phospholipases A_2 are also heavily involved in the lipidome we have quantitated. Those 358 additional phospholipases likely belong to the superfamily of secreted phospholipases A₂, which can 359 hydrolyze phospholipids containing fatty acids other than AA (56, 57) and are reported to contribute to 360 lung inflammation (58-61). However, and assuming that a large part of eicosanoids is the consequence 361 of the group IVA cytosolic phospholipase A2, our findings do not allow us to pinpoint which other 362 phospholipases are involved in the release of LA, AA, EPA, DPA and DHA.

363

364 The metabolism of EPA, DPA and DHA, which are omega-3 fatty acids, often results in the biosynthesis 365 of SPMs, most of which are anti-inflammatory and pro-resolving lipids. Their presence in high levels 366 was somewhat surprising as they are generally thought to appear during the resolution of inflammation, after the biosynthesis of prostaglandins and leukotrienes has occurred and following a class-switch from 367 368 pro-inflammatory to pro-resolving lipids (62). However, our data indicate that prostaglandins, 369 leukotrienes and SPMs can certainly co-exist and participate in the inflammatory cascade during the 370 acute phase of inflammation/infection in which resolution has not been fully engaged. Moreover, given their strong documented anti-inflammatory effects and their host-defense boosting functions, they could 371 372 be viewed as potential mediators to enhance to limit the infection. To that end, it was recently proposed 373 that dexamethasone could participate in the upregulation of SPM biosynthesis and effects in moderate to 374 severe COVID-19 patients, although this needs to be confirmed (63). While omega-3 fatty acids, notably 375 purified preparation enriched in EPA and DHA are commercially available as dietary supplements, we 376 did not see a correlation between SPMs and the levels of EPA or DHA, indicating that SPMs levels are 377 likely more dependent on biosynthetic enzymes other than phospholipases such as lipoxygenases than EPA or DHA availability. As of today, no resolution pharmacology treatment has been approved by 378 379 governmental health agencies yet. However, some putative E- and D-series resolvin precursors, notably 380 18-HEPE and 17-HDHA, are available as dietary supplements.

381

15

382 In addition to cyclooxygenase and lipoxygenase derivatives, other bioactive lipids are recognized, at least 383 in mice, to downregulate the immune response. This is notably the case of the endocannabinoids N-384 arachidonoyl-ethanolamine (AEA) and 2-arachidonoyl-glycerol (2-AG), which are AA-derived lipids 385 (64). The anti-inflammatory effects of AEA and 2-AG are mostly related to the activation of the CB_2 386 receptor, which is heavily expressed by leukocytes (65). In addition to 2-AG and AEA, their congeners 387 from the monacyl-glycerols and N-acyl-ethanolamines and N-acyl-aminoacids families, now viewed as 388 the endocannabinoidome, could potentially regulate the inflammatory response during SARS-CoV-2 389 infections, notably by activating other anti-inflammatory receptors (66). It will thus be crucial to decipher 390 whether the endocannabinoidome is modulated during COVID-19 and if a potential target such as CB_2 391 receptor agonists, or endocannabinoid hydrolase inhibitors could be helpful in the treatment of COVID-392 19 or other coronavirus-mediated infections.

393

394 Nonetheless the expanded definition of a dysregulated lipidome we unravel in SARS-CoV-2 infections 395 requiring mechanical ventilation, our study has limitations. 1) BALs from healthy controls are from 396 younger individuals than those from severe COVID-19 patients. This could have an impact on some 397 mediators, notably PGD₂ levels, which are increased in aged mice and worsen SARS-CoV infections 398 (67); 2) The procedure to obtain BAL fluids is slightly different between healthy controls and severe 399 COVID-19 patients. Indeed, while the volume of saline injected to healthy people was 50 ml, that of 400 severe COVID-19 patients was 100 ml. The possible outcome of this discrepancy could be and 401 underestimation of lipid levels in one group vs. the other. While some might argue that the first saline 402 bolus contains more lipids than the following one(s), other might argue that lipid levels are consistent in 403 each bolus. Given that, in our hands, the number of BAL cells is usually greater in the first bolus than in 404 the subsequent ones (when multiple boli are utilized), we are confident that the BAL fluid from the first 405 bolus likely contains more lipids than the second one. This would thus lead to a slight underestimation 406 of lipids in the COVID-19 group. 3) Unfortunately, the leukocyte counts in the BALs of severe COVID-407 19 patients did not include the number of alveolar macrophages and it is thus impossible to determine a 408 clear differential count of leukocytes in those samples. Furthermore, the eosinophil counts were 409 somewhat limited by the apparatus as it could estimate the counts to $+/-10^{5}$ /ml cells, which likely has an 410 impact on the different correlations involving eosinophils, notably with EXE₄; 4) We could not compare 411 the levels of lipids in the BALs of severe COVID-19 patients to those found in the blood. This appears 412 important given the limited number of correlations found between BAL lipids and other circulating 413 markers such as CRP and D-dimers. To that end, a recent study indicated differences in some of the

16

- 414 herein investigated bioactive lipids in the circulation (68). It will thus be important to pursue our
- 415 investigations and determine whether there is a transposition of the BAL lipidome to the circulation.
- 416
- 417 In conclusion, our data unmask that in addition to the recognized cytokine storm previously documented,
- 418 lung fluids of SARS-CoV-2-infected patients indicate that a lipid storm also occurs. As highlighted
- 419 above, the rich library of governmental health agencies-approved lipid modulators might provide
- 420 beneficial and usually low-cost add-ons to the current therapeutic arsenal utilized to diminish the severity
- 421 of COVID-19 and possibly additional coronavirus-mediated infections.
- 422
- 423
- 424
- 425

426 ACKNOWLEDGEMENTS

427 ASA, AC, VR, ML, and NF are members of the Quebec Respiratory Health research Network.

17

428 **REFERENCES**

- 429
- 430
- 431
- 432 1. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, Hu Y, Tao ZW, Tian JH, Pei YY, Yuan ML,
 433 Zhang YL, Dai FH, Liu Y, Wang QM, Zheng JJ, Xu L, Holmes EC, Zhang YZ. A new
 434 coronavirus associated with human respiratory disease in China. *Nature* 2020; 579: 265-269.
- 434 Coronavirus associated with numan respiratory disease in China. *Nature* 2020, 579: 205-209.
 435 2. Verdoni L, Mazza A, Gervasoni A, Martelli L, Ruggeri M, Ciuffreda M, Bonanomi E, D'Antiga L.
- 436 An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2
 437 epidemic: an observational cohort study. *Lancet* 2020; 395: 1771-1778.
- 438
 438 3. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J,
 439 Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R,
 440 Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus
 441 in Wuhan, China. *Lancet* 2020; 395: 497-506.
- 4. Zhang XSD, C. SARS-CoV-2 and Health Care Worker Protection in Low-Risk Settings: a Review of Modes of Transmission and a Novel Airborne Model Involving Inhalable Particles. *Clinical Microbiology Reviews* 2020; 34.
- 5. Oberfeld B, Achanta A, Carpenter K, Chen P, Gilette NM, Langat P, Said JT, Schiff AE, Zhou AS,
 Barczak AK, Pillai S. SnapShot: COVID-19. *Cell* 2020; 181: 954-954 e951.
- 6. Damiani S, Fiorentino M, De Palma A, Foschini MP, Lazzarotto T, Gabrielli L, Viale PL, Attard L,
 Riefolo M, D'Errico A. Pathological Post Mortem Findings in Lungs Infected With Sars-Cov 2. *J Pathol* 2020.
- 450 7. Barton LM, Duval EJ, Stroberg E, Ghosh S, Mukhopadhyay S. COVID-19 Autopsies, Oklahoma,
 451 USA. *Am J Clin Pathol* 2020; 153: 725-733.
- 8. Zhang H, Zhou P, Wei Y, Yue H, Wang Y, Hu M, Zhang S, Cao T, Yang C, Li M, Guo G, Chen X,
 Chen Y, Lei M, Liu H, Zhao J, Peng P, Wang CY, Du R. Histopathologic Changes and SARSCoV-2 Immunostaining in the Lung of a Patient With COVID-19. *Ann Intern Med* 2020; 172:
 629-632.
- 456 9. Amigues I, Pearlman AH, Patel A, Reid P, Robinson PC, Sinha R, Kim AH, Youngstein T,
 457 Jayatilleke A, Konig MF. Coronavirus disease 2019: investigational therapies in the prevention 458 and treatment of hyperinflammation. *Expert Rev Clin Immunol* 2020.
- 459 10. Serhan CN, Levy BD. Resolvins in inflammation: emergence of the pro-resolving superfamily of
 460 mediators. *J Clin Invest* 2018; 128: 2657-2669.
- 461 11. Archambault AS, Turcotte C, Martin C, Provost V, Larose MC, Laprise C, Chakir J, Bissonnette E,
 462 Laviolette M, Bosse Y, Flamand N. Comparison of eight 15-lipoxygenase (LO) inhibitors on
 463 the biosynthesis of 15-LO metabolites by human neutrophils and eosinophils. *PLoS One* 2018;
 464 13: e0202424.
- 12. Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, Lavin Y, Swartz TH, Madduri D, Stock A, Marron TU, Xie H, Patel M, Tuballes K, Van Oekelen O, Rahman A, Kovatch P, Aberg JA, Schadt E, Jagannath S, Mazumdar M, Charney AW, Firpo-Betancourt A, Mendu DR, Jhang J, Reich D, Sigel K, Cordon-Cardo C, Feldmann M, Parekh S, Merad M, Gnjatic S. An inflammatory cytokine signature predicts COVID-19 severity and survival. *Nat Med* 2020.
- 471 13. Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C. Cytokine Storm in COVID-19: The Current Evidence
 472 and Treatment Strategies. *Front Immunol* 2020; 11: 1708.
- 14. Zaid Y, Puhm F, Allaeys I, Naya A, Oudghiri M, Khalki L, Limami Y, Zaid N, Sadki K, Ben El
 Haj R, Mahir W, Belayachi L, Belefquih B, Benouda A, Cheikh A, Langlois MA, Cherrah Y,
 Flamand L, Guessous F, Boilard E. Platelets Can Associate with SARS-Cov-2 RNA and Are
 Hyperactivated in COVID-19. *Circ Res* 2020.

- 18
- 477 15. Xiong Y, Liu Y, Cao L, Wang D, Guo M, Jiang A, Guo D, Hu W, Yang J, Tang Z, Wu H, Lin Y,
 478 Zhang M, Zhang Q, Shi M, Liu Y, Zhou Y, Lan K, Chen Y. Transcriptomic characteristics of
 479 bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients.
 480 *Emerg Microbes Infect* 2020; 9: 761-770.
- 16. Liao M, Liu Y, Yuan J, Wen Y, Xu G, Zhao J, Cheng L, Li J, Wang X, Wang F, Liu L, Amit I,
 Zhang S, Zhang Z. Single-cell landscape of bronchoalveolar immune cells in patients with
 COVID-19. *Nat Med* 2020; 26: 842-844.
- 484 17. Miller DB, Munster D, Wasvary JS, Simke JP, Peppard JV, Bowen BR, Marshall PJ. The
 485 heterologous expression and characterization of human prostaglandin G/H synthase-2 (COX-2).
 486 *Biochem Biophys Res Commun* 1994; 201: 356-362.
- 18. Newman SP, Flower RJ, Croxtall JD. Dexamethasone suppression of IL-1b-induced
 cyclooxygenase 2 expression is not mediated by lipocortin-1 in A549 cells. *Biochem Biophys Res Commun* 1994; 202: 931-939.
- 490 19. Mitchell JA, Belvisi MG, Akarasereenont P, Robbins RA, Kwon OJ, Croxtall J, Barnes PJ, Vane
 491 JR. Induction of cyclo-oxygenase-2 by cytokines in human pulmonary epithelial cells:
 492 regulation by dexamethasone. *Br J Pharmacol* 1994; 113: 1008-1014.
- 20. Stephenson AH, Lonigro AJ, Hyers TM, Webster RO, Fowler AA. Increased concentrations of
 leukotrienes in bronchoalveolar lavage fluid of patients with ARDS or at risk for ARDS. *Am Rev Respir Dis* 1988; 138: 714-719.
- 496 21. Ratnoff WD, Matthay MA, Wong MY, Ito Y, Vu KH, Wiener-Kronish J, Goetzl EJ.
 497 Sulfidopeptide-leukotriene peptidases in pulmonary edema fluid from patients with the adult 498 respiratory distress syndrome. *J Clin Immunol* 1988; 8: 250-258.
- 499 22. Funk CD, Ardakani A. A Novel Strategy to Mitigate the Hyperinflammatory Response to COVID 500 19 by Targeting Leukotrienes. *Front Pharmacol* 2020; 11: 1214.
- 501 23. Feltenmark S, Gautam N, Brunnstrom A, Griffiths W, Backman L, Edenius C, Lindbom L,
 502 Bjorkholm M, Claesson HE. Eoxins are proinflammatory arachidonic acid metabolites
 503 produced via the 15-lipoxygenase-1 pathway in human eosinophils and mast cells. *Proc Natl* 504 Acad Sci U S A 2008; 105: 680-685.
- 24. Panigrahy D, Gilligan MM, Huang S, Gartung A, Cortes-Puch I, Sime PJ, Phipps RP, Serhan CN,
 Hammock BD. Inflammation resolution: a dual-pronged approach to averting cytokine storms
 in COVID-19? *Cancer Metastasis Rev* 2020; 39: 337-340.
- 508 25. Manne BK, Denorme F, Middleton EA, Portier I, Rowley JW, Stubben C, Petrey AC, Tolley ND,
 509 Guo L, Cody M, Weyrich AS, Yost CC, Rondina MT, Campbell RA. Platelet gene expression
 510 and function in patients with COVID-19. *Blood* 2020; 136: 1317-1329.
- 26. Hottz ED, Azevedo-Quintanilha IG, Palhinha L, Teixeira L, Barreto EA, Pao CRR, Righy C,
 Franco S, Souza TML, Kurtz P, Bozza FA, Bozza PT. Platelet activation and platelet-monocyte
 aggregate formation trigger tissue factor expression in patients with severe COVID-19. *Blood*2020; 136: 1330-1341.
- 27. Nagata K, Hirai H, Tanaka K, Ogawa K, Aso T, Sugamura K, Nakamura M, Takano S. CRTH2, an
 orphan receptor of T-helper-2-cells, is expressed on basophils and eosinophils and responds to
 mast cell-derived factor(s). *FEBS Lett* 1999; 459: 195-199.
- 28. Monneret G, Gravel S, Diamond M, Rokach J, Powell WS. Prostaglandin D₂ is a potent
 chemoattractant for human eosinophils that acts via a novel DP receptor. *Blood* 2001; 98: 19421948.
- 29. Hirai H, Tanaka K, Yoshie O, Ogawa K, Kenmotsu K, Takamori Y, Ichimasa M, Sugamura K,
 Nakamura M, Takano S, Nagata K. Prostaglandin D₂ selectively induces chemotaxis in T helper
 type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. *J Exp Med*2001; 193: 255-261.

- 19
- 525 30. Chang JE, Doherty TA, Baum R, Broide D. Prostaglandin D₂ regulates human type 2 innate 526 lymphoid cell chemotaxis. J Allergy Clin Immunol 2014; 133: 899-901 e893. 527 31. Medeiros A, Peres-Buzalaf C, Fortino Verdan F, Serezani CH. Prostaglandin E_2 and the 528 suppression of phagocyte innate immune responses in different organs. Mediators Inflamm 2012; 2012: 327568. 529 530 32. Group RC, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling 531 C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, 532 Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, 533 Haynes R, Landray MJ. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary 534 Report. N Engl J Med 2020. 535 33. Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC, Avezum A, Lopes RD, 536 Bueno FR, Silva M, Baldassare FP, Costa ELV, Moura RAB, Honorato MO, Costa AN, 537 Damiani LP, Lisboa T, Kawano-Dourado L, Zampieri FG, Olivato GB, Righy C, Amendola 538 CP, Roepke RML, Freitas DHM, Forte DN, Freitas FGR, Fernandes CCF, Melro LMG, Junior 539 GFS, Morais DC, Zung S, Machado FR, Azevedo LCP, Investigators CC-BI. Effect of 540 Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute 541 Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. JAMA 542 2020; 324: 1307-1316. 543 34. Group WHOREAfC-TW, Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC, 544 Annane D, Azevedo LCP, Berwanger O, Cavalcanti AB, Dequin PF, Du B, Emberson J, Fisher 545 D, Giraudeau B, Gordon AC, Granholm A, Green C, Haynes R, Heming N, Higgins JPT, Horby 546 P. Juni P. Landrav MJ. Le Gouge A. Leclerc M. Lim WS. Machado FR. McArthur C. Meziani 547 F, Moller MH, Perner A, Petersen MW, Savovic J, Tomazini B, Veiga VC, Webb S, Marshall 548 JC. Association Between Administration of Systemic Corticosteroids and Mortality Among 549 Critically Ill Patients With COVID-19: A Meta-analysis. JAMA 2020; 324: 1330-1341. 550 35. Crofford LJ, Wilder RL, Ristimaki AP, Sano H, Remmers EF, Epps HR, Hla T. Cyclooxygenase-1 551 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1b, phorbol ester, and 552 corticosteroids. J Clin Invest 1994; 93: 1095-1101. 553 36. Masferrer JL, Reddy ST, Zweifel BS, Seibert K, Needleman P, Gilbert RS, Herschman HR. In vivo 554 glucocorticoids regulate cyclooxygenase-2 but not cyclooxygenase-1 in peritoneal 555 macrophages. J Pharmacol Exp Ther 1994; 270: 1340-1344. 556 37. Wilborn J, Crofford LJ, Burdick MD, Kunkel SL, Strieter RM, Peters-Golden M. Cultured lung 557 fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminished capacity 558 to synthesize prostaglandin E₂ and to express cyclooxygenase-2. J Clin Invest 1995; 95: 1861-559 1868. 560 38. Little P. Non-steroidal anti-inflammatory drugs and covid-19. BMJ 2020; 368: m1185. 561 39. Lund LC, Kristensen KB, Reilev M, Christensen S, Thomsen RW, Christiansen CF, Stovring H, 562 Johansen NB, Brun NC, Hallas J, Pottegard A. Adverse outcomes and mortality in users of non-563 steroidal anti-inflammatory drugs who tested positive for SARS-CoV-2: A Danish nationwide 564 cohort study. PLoS Med 2020; 17: e1003308. 565 40. Chow JH, Khanna AK, Kethireddy S, Yamane D, Levine A, Jackson AM, McCurdy MT, Tabatabai A, Kumar G, Park P, Benjenk I, Menaker J, Ahmed N, Glidewell E, Presutto E, Cain S, 566 567 Haridasa N, Field W, Fowler JG, Trinh D, Johnson KN, Kaur A, Lee A, Sebastian K, Ulrich A, 568 Pena S, Carpenter R, Sudhakar S, Uppal P, Fedeles BT, Sachs A, Dahbour L, Teeter W, Tanaka 569 K, Galvagno SM, Herr DL, Scalea TM, Mazzeffi MA. Aspirin Use is Associated with 570 Decreased Mechanical Ventilation, ICU Admission, and In-Hospital Mortality in Hospitalized 571 Patients with COVID-19. Anesth Analg 2020. 572 41. Gupta A, Kalantar-Zadeh K, Reddy ST. Ramatroban as a Novel Immunotherapy for COVID-19. J 573 *Mol Genet Med* 2020; 14.

- 42. Yang J, Eiserich JP, Cross CE, Morrissey BM, Hammock BD. Metabolomic profiling of regulatory
 lipid mediators in sputum from adult cystic fibrosis patients. *Free Radic Biol Med* 2012; 53:
 160-171.
- 577 43. Saak A, Schonfeld W, Knoller J, Steinkamp G, von der Hardt H, Konig W. Generation and
 578 metabolism of leukotrienes in granulocytes of patients with cystic fibrosis. *Int Arch Allergy*579 *Appl Immunol* 1990; 93: 227-236.
- 44. Knoller J, Schonfeld W, Koller M, Hensler T, Konig W. Arachidonic acid metabolites from
 polymorphonuclear leukocytes of healthy donors, severely burned patients and children with
 cystic fibrosis--routine monitoring by high-performance liquid chromatography. *J Chromatogr*1988; 427: 199-208.
- 45. Brom J, Konig W, Koller M, Gross-Weege W, Erbs G, Muller F. Metabolism of leukotriene B₄ by
 polymorphonuclear granulocytes of severely burned patients. *Prostaglandins Leukot Med* 1987;
 27: 209-225.
- 46. Archambault AS, Poirier S, Lefebvre JS, Robichaud PP, Larose MC, Turcotte C, Martin C, Provost
 V, Boudreau LH, McDonald PP, Laviolette M, Surette ME, Flamand N. 20-Hydroxy- and 20carboxy-leukotriene (LT) B₄ downregulate LTB₄-mediated responses of human neutrophils and
 eosinophils. *J Leukoc Biol* 2019; 105: 1131-1142.
- 591 47. Bouchette D, Preuss CV. Zileuton. StatPearls. Treasure Island (FL); 2020.
- 48. Halpin DMG, Criner GJ, Papi A, Singh D, Anzueto A, Martinez FJ, Agusti AA, Vogelmeier CF,
 Committee GS. Global Initiative for the Diagnosis, Management, and Prevention of Chronic
 Obstructive Lung Disease: The 2020 GOLD Science Committee Report on COVID-19 &
 COPD. *Am J Respir Crit Care Med* 2020.
- 49. Ham EA, Soderman DD, Zanetti ME, Dougherty HW, McCauley E, Kuehl FA, Jr. Inhibition by
 prostaglandins of leukotriene B₄ release from activated neutrophils. *Proc Natl Acad Sci U S A* 1983; 80: 4349-4353.
- 50. Fonteh AN, Winkler JD, Torphy TJ, Heravi J, Undem BJ, Chilton FH. Influence of isoproterenol
 and phosphodiesterase inhibitors on platelet-activating factor biosynthesis in the human
 neutrophil. *J Immunol* 1993; 151: 339-350.
- 51. Denis D, Riendeau D. Phosphodiesterase 4-dependent regulation of cyclic AMP levels and
 leukotriene B₄ biosynthesis in human polymorphonuclear leukocytes. *Eur J Pharmacol* 1999;
 367: 343-350.
- 52. Flamand N, Boudreault S, Picard S, Austin M, Surette ME, Plante H, Krump E, Vallee MJ, Gilbert
 C, Naccache P, Laviolette M, Borgeat P. Adenosine, a potent natural suppressor of arachidonic
 acid release and leukotriene biosynthesis in human neutrophils. *Am J Respir Crit Care Med*2000; 161: S88-94.
- 53. Flamand N, Plante H, Picard S, Laviolette M, Borgeat P. Histamine-induced inhibition of
 leukotriene biosynthesis in human neutrophils: involvement of the H₂ receptor and cAMP. Br J
 Pharmacol 2004; 141: 552-561.
- 54. Turcotte C, Zarini S, Jean S, Martin C, Murphy RC, Marsolais D, Laviolette M, Blanchet MR,
 Flamand N. The Endocannabinoid Metabolite Prostaglandin E₂ (PGE₂)-Glycerol Inhibits
 Human Neutrophil Functions: Involvement of Its Hydrolysis into PGE₂ and EP Receptors. J *Immunol* 2017; 198: 3255-3263.
- 55. Flamand N, Picard S, Lemieux L, Pouliot M, Bourgoin SG, Borgeat P. Effects of pyrrophenone, an
 inhibitor of group IVA phospholipase A₂, on eicosanoid and PAF biosynthesis in human
 neutrophils. *Br J Pharmacol* 2006; 149: 385-392.
- 56. Hanasaki K, Ono T, Saiga A, Morioka Y, Ikeda M, Kawamoto K, Higashino K, Nakano K,
 Yamada K, Ishizaki J, Arita H. Purified group X secretory phospholipase A₂ induced prominent
 release of arachidonic acid from human myeloid leukemia cells. *J Biol Chem* 1999; 274: 3420334211.

- 21
- 57. Murakami M, Masuda S, Shimbara S, Bezzine S, Lazdunski M, Lambeau G, Gelb MH, Matsukura
 S, Kokubu F, Adachi M, Kudo I. Cellular arachidonate-releasing function of novel classes of
 secretory phospholipase A₂s (groups III and XII). *J Biol Chem* 2003; 278: 10657-10667.
- 58. Nolin JD, Murphy RC, Gelb MH, Altemeier WA, Henderson WR, Jr., Hallstrand TS. Function of
 secreted phospholipase A₂ group-X in asthma and allergic disease. *Biochim Biophys Acta Mol Cell Biol Lipids* 2019; 1864: 827-837.
- 59. Hallstrand TS, Lai Y, Altemeier WA, Appel CL, Johnson B, Frevert CW, Hudkins KL, Bollinger
 JG, Woodruff PG, Hyde DM, Henderson WR, Jr., Gelb MH. Regulation and function of
 epithelial secreted phospholipase A₂ group X in asthma. *Am J Respir Crit Care Med* 2013; 188:
 42-50.
- 60. Arbibe L, Koumanov K, Vial D, Rougeot C, Faure G, Havet N, Longacre S, Vargaftig BB, Bereziat
 634 G, Voelker DR, Wolf C, Touqui L. Generation of lyso-phospholipids from surfactant in acute
 635 lung injury is mediated by type-II phospholipase A₂ and inhibited by a direct surfactant protein
 636 A-phospholipase A₂ protein interaction. *J Clin Invest* 1998; 102: 1152-1160.
- 637 61. Ohtsuki M, Taketomi Y, Arata S, Masuda S, Ishikawa Y, Ishii T, Takanezawa Y, Aoki J, Arai H,
 638 Yamamoto K, Kudo I, Murakami M. Transgenic expression of group V, but not group X,
 639 secreted phospholipase A₂ in mice leads to neonatal lethality because of lung dysfunction. J
 640 Biol Chem 2006; 281: 36420-36433.
- 641 62. Buckley CD, Gilroy DW, Serhan CN. Proresolving lipid mediators and mechanisms in the
 642 resolution of acute inflammation. *Immunity* 2014; 40: 315-327.
- 643 63. Andreakos E, Papadaki M, Serhan CN. Dexamethasone, pro-resolving lipid mediators and
 644 resolution of inflammation in COVID-19. *Allergy* 2020.
- 645 64. Turcotte C, Chouinard F, Lefebvre JS, Flamand N. Regulation of inflammation by cannabinoids,
 646 the endocannabinoids 2-arachidonoyl-glycerol and arachidonoyl-ethanolamide, and their
 647 metabolites. *J Leukoc Biol* 2015; 97: 1049-1070.
- 648 65. Turcotte C, Blanchet MR, Laviolette M, Flamand N. The CB₂ receptor and its role as a regulator of
 649 inflammation. *Cell Mol Life Sci* 2016; 73: 4449-4470.
- 650 66. Di Marzo V. New approaches and challenges to targeting the endocannabinoid system. *Nat Rev* 651 *Drug Discov* 2018; 17: 623-639.
- 67. Zhao J, Zhao J, Legge K, Perlman S. Age-related increases in PGD₂ expression impair respiratory
 DC migration, resulting in diminished T cell responses upon respiratory virus infection in mice.
 J Clin Invest 2011; 121: 4921-4930.
- 655 68. Schwarz B, Sharma L, Roberts L, Peng X, Bermejo S, Leighton I, Massana AC, Farhadian S, Ko A,
 656 DelaCruz C, Bosio CM. Severe SARS-CoV-2 infection in humans is defined by a shift in the
 657 serum lipidome resulting in dysregulation of eicosanoid immune mediators. *medRxiv* 2020.
- 658
- 659

22

660

661

Table 1. Clinical characteristics of BAL donors

	Severe COVID-19	Healthy controls
Ν	33	25
Women/Men	16/17	16/9
Death (Y/N)	2/31	N/A
SARS-CoV-2 detection in BAL (Ct)	25.303 ± 0.906	N/A
Age	58.455 ± 3.175	26.130 ± 1.030
Weight (kg)	73.097 ± 2.873	N/A
Hospital stay (days)	20.545 ± 2.014	N/A
Days before BAL	3.485 ± 0.763	N/A
D-Dimers (mg/ml)	1.210 ± 0.129	N/A
CRP (mg/l)	20.652 ± 2.525	N/A
ALT (U/I)	32.582 ± 2.144	N/A
AST (U/I)	35.145 ± 2.978	N/A
LDH (U/I)	616.152 ± 41.175	N/A
Hemoglobin (g/l)	123.152 ± 2.365	N/A
Blood Monocytes (million/ml)	0.327 ± 0.034	N/A
Blood Neutrophils (million/ml)	2.855 ± 0.194	N/A
Blood Eosinophils (million/ml)	0.026 ± 0.003	N/A
Blood Platelets (million/ml)	181.848 ± 13.397	N/A
Blood Lymphocytes (million/ml)	1.127 ± 0.127	N/A
Platelet to Lymphocyte ratio	223.893 ± 34.934	N/A
BAL Neutrophils (million/ml)	24.694 ± 2.152	N/A
BAL Eosinophils (million/ml)	0.197 ± 0.077	N/A
BAL Lymphocytes (million/ml)	21.830 ± 2.393	N/A

662

Data are presented as the mean ± SEM. ALT, alanine transaminase; AST, aspartate transaminase; CRP, C-reactive protein; LDH, Lactate dehydrogenase; N/A, not available;

663

665 Table 2. Mass transition of the investigated lipid mediators.

666

Compounds	ISTD used	Q1 > Q3	Retention time (min)	LLOQ (fmol)
TXB ₂ -D ₄		373.10>199.35	4,083	
TXB ₂	TXB ₂ -D ₄	369.20>195.30	4,090	250
PGE ₂ -D ₄		355.20>275.35	4,627	
6-keto PGF _{1α}	PGE ₂ -D ₄	369.30>163.10	3,493	250
PGF _{3α}	PGE ₂ -D ₄	351.30>193.30	3,954	50
PGE ₃	PGE ₂ -D ₄	349.30>269.35	4,160	25
PGF _{2α}	PGE ₂ -D ₄	353.40>309.30	4,412	250
PGE ₁	PGE ₂ -D ₄	353.30>273.40	4,770	50
PGE ₂	PGE ₂ -D ₄	351.20>271.15	4,627	50
PGD ₂	PGE ₂ -D ₄	351.30>271.20	4,847	50
$1a, 1b$ -dihomo-PGF _{2α}	PGE ₂ -D ₄	381.20>337.40	5,428	50
RvD2-D₅		380.40>175.20	4,685	
RvE1	RvD2-D₅	349.30>195.20	3,529	250
RvD3	RvD2-D₅	375.40>147.20	4,689	250
RvD2	RvD2-D₅	375.40>175.20	4,780	500
RvD1	RvD2-D₅	375.40>141.10	5,126	500
RvD4	RvD2-D₅	375.40>101.05	5,588	250
Maresin 1	RvD2-D₅	359.40>177.25	6,684	500
PDX	RvD2-D₅	359.30>153.15	6,877	25
RvD5	RvD2-D₅	359.40>199.25	6,899	250
Maresin 2	RvD2-D₅	359.40>221.05	7,433	250
LTC ₄ -D ₅		629.30>272.20	4,999	
EXD4	LTC ₄ -D ₅	495.30>176.90	4,918	250
EXC ₄	LTC ₄ -D ₅	624.30>272.25	5,025	500
LTC ₄	LTC ₄ -D ₅	624.30>272.20	5,065	500
LXA ₄	LTB4-D4	351.50>115.05	5,051	250
EXE_4	LTC ₄ -D ₅	438.30>351.10	5,263	700
LTD ₄	LTC ₄ -D ₅	495.30>176.85	5,359	250
LTE ₄	LTC ₄ -D ₅	438.30>333.20	5,677	500
LTB ₄ -D ₄		339.30>197.20	6,742	
20-COOH-LTB ₄	LTB ₄ -D ₄	365.00>347.25	3,549	250
20-OH-LTB ₄	LTB4-D4	351.10>195.15	3,670	50
LTB₅	LTB ₄ -D ₄	333.40>195.25	5,992	250
LTB ₄	LTB4-D4	335.30>195.25	6,765	25
12-oxo-LTB ₄	LTB4-D4	333.40>179.20	7,399	250
LTB ₃	LTB4-D4	337.40>195.20	7,523	250
13-HODE-D4		299.10>198.15	9,196	
13(S)-HOTrE	13-HODE-D4	292.90>195.25	8,474	250
9-HODE	13-HODE-D ₄	295.30>171.35	9,237	25

13-HODE	13-HODE-D4	295.50>195.30	9,238	25
13-KODE	13-HODE-D4	295.20>277.30	9,584	25
15-HETE-D ₈		327.20>226.20	9,503	
8,15-DiHETE	15-HETE-D8	335.40>317.30	6,480	250
5(S),15(S)-DiHETE	15-HETE-D ₈	335.20>255.30	6,630	250
5(S),12(S)-DiHETE	15-HETE-D ₈	334.99>195.10	7,023	250
12(S)-HHTrE	15-HETE-D ₈	279.20>179.25	7,699	250
14(15)-DIHET	15-HETE-D ₈	337.40>207.30	7,712	25
5(S),6(R)-DiHETE	15-HETE-D ₈	335.00>145.10	8,020	250
18-HEPE	15-HETE-D ₈	317.30>259.40	8,497	250
15-HEPE	15-HETE-D ₈	317.40>219.25	8,840	250
12-HEPE	15-HETE-D ₈	317.30>179.35	9,015	250
15-HETE	15-HETE-D ₈	319.40>219.30	9,574	250
15-KETE	15-HETE-D ₈	317.20>113.00	9,707	25
17-HDHA	15-HETE-D ₈	343.50>281.30	9,719	500
14-HDHA	15-HETE-D ₈	343.50>281.30	9,878	250
11-HETE	15-HETE-D ₈	319.30>167.35	9,770	25
8-HETE	15-HETE-D ₈	319.30>155.25	9,841	50
12-HETE	15-HETE-D ₈	319.10>179.25	9,924	250
5-HETE	15-HETE-D ₈	319.30>115.05	10,008	250
17-HDPA	15-HETE-D ₈	345.20>327.10	10,086	250
15-HETrE	15-HETE-D ₈	321.50>303.40	10,095	25
14(15)-EET	15-HETE-D ₈	319.40>219.25	10,623	500
EPA-D₅		306.20>262.20	12,128	
EPA	EPA-D₅	301.20>257.30	12,156	25
DHA-D₅		332.20>288.20	12,889	
DHA	DHA-D₅	327.50>283.30	12,919	50
DPA(n-3)-D₅		334.40>290.35	13,178	
DPA(n-3)	DPA(n-3)-D ₅	329.50>285.15	13,191	25
AA-D ₈		311.20>267.25	13,006	
AA	AA-D ₈	303.20>259.30	13,052	250
LA	AA-D ₈	279.40>261.35	13,079	2500





Figure 1. Levels of cyclooxygenase-derived metabolites in the BAL fluids of healthy and severe COVID-19 patients. BALs were obtained and processed as described in *Methods*. A) Results are from the BALs from 25 healthy subjects and 33 severe COVID-19 patients. P values were obtained by performing a Mann-Whitney test: **** = p < 0.0001. B-E) Correlation tests were performed with COVID-19 patients by using the non-parametric Spearman's rank. P<0.05 was the threshold of significance. The linear regression is represented with a solid line and the best-fit lines of 95% confidence are represented with dotted lines.

- 679
- 680
- 681
- 682
- 683

26



Figure 2. Comparison of leukotriene and eoxin levels in the BAL fluids of healthy subjects and 686 687 severe COVID-19 patients. A,D) BALs were obtained and processed as described in methods. Lipids 688 then were extracted and quantitated by LC-MS/MS. Results are from the BALs from 25 healthy subjects and 33 severe COVID19 patients. P values were obtained by performing a Mann-Whitney test: * p < 689 0.05; *** p < 0.001; **** p < 0.0001 **B.C.E-G**) Correlation tests were performed with severe COVID-690 691 19 patients by using the non-parametric Spearman's rank. P<0.05 was the threshold of significance. The linear regression is represented with a solid line and the best-fit lines of 95% confidence are represented 692 693 with dotted lines.

694

685

684



- 696 Figure 3. Fatty acid levels in the BAL fluids of healthy subjects and severe COVID-19 patients.
- 697 BALs were obtained and processed as described in *Methods*. Lipids then were extracted and quantitated
- 698 by LC-MS/MS. Results are from the BALs from 25 healthy subjects and 33 severe COVID19 patients.
- 699 P values were obtained by performing a Mann-Whitney test: **** p < 0.0001.
- 700

medRxiv preprint doi: https://doi.org/10.1101/2020.12.04.20242115; this version posted December 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



701 702 Figure 4. Comparison of 12- and 15-lipoxygenase-derived oxylipins and diHETEs levels in the 703 BALs of healthy subjects and severe COVID-19 patients. A-D) BALs were obtained and processed as described in Methods. Lipids then were extracted and quantitated by LC-MS/MS. Results are from the 704 705 BALs from 25 healthy subjects and 33 Severe COVID-19 patients. P values were obtained by performing a Mann-Whitney test: **** p < 0.0001. 706

707

708





712 Figure 5. Comparison of specialized pro-resolving lipid mediator levels in the BAL fluids of healthy subjects and severe COVID19 patients. A) BALs were obtained and processed as described in 713 714 Methods. Lipids then were extracted and quantitated by LC-MS/MS. Results are from the BALs from 25 715 healthy subjects and 33 severe COVID-19 patients. . P values were obtained by performing a Mann-Whitney test: * p < 0.05; ** p < 0.01; **** p < 0.0001. **B-G**) Correlation tests were performed with 716 717 severe COVID-19 patients by using the non-parametric Spearman's rank. P<0.05 was the threshold of significance. The linear regression is represented with a solid line and the best-fit lines of 95% confidence

718

719 are represented with dotted lines.



Figure 6. Correlation between selected bioactive lipids in the BALs of severe COVID-19 patients. Correlation tests were performed by using the non-parametric Spearman's rank using the Graphpad Prism Software. P<0.05 was the threshold of significance. Positive correlations

722 are shown using shades of green.

31

723

	Age	Weight	Days in Hospital	D- Dimers	CRP	ALT	AST	LDH	нь	Blood MONO	Blood NEU	Blood EOS	Blood Platelets	Blood Lymph	PLR	BAL NEU	BAL EOS	BAL Lymp
PGD ₂	-0,061	-0,188	0,161	0,096	0,007	-0,019	-0,084	0,102	-0,254	-0,140	0,318	0,342	0,108	-0,173	0,112	0,029	0,232	-0,0
PGE ₂	-0,042	-0,359	0,101	0,061	-0,068	-0,280	-0,392	-0,020	0,019	-0,271	0,271	0,030	0,145	-0,283	0,311	-0,059	0,188	-0,1
$PGF_{2\alpha}$	-0,147	-0,329	0,090	0,065	-0,151	-0,283	-0,406	0,054	0,052	-0,303	0,134	-0,027	0,061	-0,311	0,328	-0,182	0,207	-0,0
TXB ₂	-0,057	-0,295	0,058	0,116	-0,009	-0,142	-0,248	0,096	-0,098	-0,254	0,307	0,119	0,141	-0,233	0,247	-0,063	0,187	-0,1
2-HHTrE	-0,017	-0,370	0,117	0,078	-0,070	-0,284	-0,359	-0,024	-0,033	-0,227	0,287	0,057	0,134	-0,290	0,299	-0,044	0,159	-0,1
LTB₄	-0,029	-0,204	0,076	0,124	0,041	-0,002	-0,054	0,146	-0,221	-0,155	0,313	0,291	0,150	-0,138	0,112	0,002	0,217	-0,0
0-COOH- LTB4	0,092	-0,207	0,083	0,205	0,049	-0,059	-0,231	0,215	0,161	-0,109	0,355	0,105	-0,010	-0,252	0,289	-0,176	0,162	-0,0
LTE4	-0,037	-0,164	0,043	-0,175	-0,180	-0,392	-0,329	-0,310	0,345	-0,135	0,007	-0,511	0,017	0,001	0,087	0,052	-0,121	-0,0
EXE4	-0,109	0,331	0,032	0,109	0,201	0,232	0,306	0,260	-0,339	0,006	0,144	0,377	0,111	0,256	-0,229	0,347	0,339	-0,2
LA	-0,038	-0,398	0,059	-0,058	-0,119	-0,541	-0,593	-0,246	0,286	-0,264	0,012	-0,301	0,076	-0,310	0,403	-0,127	0,046	-0,0
AA	-0,094	-0,361	0,029	-0,115	-0,092	-0,562	-0,581	-0,225	0,242	-0,280	-0,103	-0,300	0,079	-0,267	0,345	-0,097	0,094	-0,1
EPA	-0,101	-0,400	0,012	-0,040	-0,093	-0,571	-0,592	-0,216	0,250	-0,303	-0,040	-0,275	0,071	-0,340	0,409	-0,141	0,065	-0,1
DPA(n-3)	-0,154	-0,320	0,010	-0,133	-0,132	-0,553	-0,560	-0,296	0,156	-0,264	-0,055	-0,335	0,160	-0,229	0,347	-0,042	0,087	-0,
DHA	-0,076	-0,343	0,006	-0,018	-0,086	-0,545	-0,527	-0,192	0,187	-0,254	0,042	-0,196	0,125	-0,286	0,353	-0,174	0,118	-0,0
5-HETE	-0,053	-0,192	0,090	0,137	0,029	0,033	-0,038	0,187	-0,233	-0,168	0,307	0,343	0,077	-0,160	0,086	-0,040	0,230	-0,0
8-HETE	-0,028	-0,187	0,140	0,200	-0,008	0,033	-0,019	0,211	-0,249	-0,120	0,285	0,342	0,051	-0,138	0,057	0,015	0,193	-0,1
11-HETE	-0,009	-0,346	0,093	0,113	-0,040	-0,179	-0,248	0,070	-0,063	-0,274	0,263	0,112	0,127	-0,243	0,228	-0,088	0,154	-0,0
12-HETE	0,000	-0,301	0,059	0,167	-0,053	-0,035	-0,110	0,190	-0,160	-0,195	0,255	0,191	0,137	-0,180	0,140	-0,055	0,197	-0,
15-HETE	-0,031	-0,381	0,059	0,080	-0,056	-0,225	-0,323	0,037	-0,021	-0,292	0,251	0,059	0,106	-0,320	0,297	-0,100	0,146	-0,
15-KETE	-0,098	-0,270	0,108	0,166	-0,074	-0,228	-0,343	0,047	0,006	-0,300	0,209	0,027	0,168	-0,158	0,172	-0,094	0,227	-0,
9-HODE	-0,035	-0,233	0,065	0,185	-0,004	0,060	-0,025	0,215	-0,234	-0,168	0,323	0,245	0,104	-0,173	0,128	-0,069	0,229	-0,0
3-HODE	-0,063	-0,299	0,085	0,145	-0,038	-0,209	-0,302	0,067	-0,030	-0,252	0,271	0,039	0,136	-0,240	0,262	-0,038	0,207	-0,
3-KODE	-0,158	-0,301	0,196	0,080	-0,080	-0,264	-0,452	-0,053	0,043	-0,288	0,186	0,005	0,092	-0,204	0,280	-0,008	0,269	-0,
13(S)- HOTrE	0,012	-0,045	0,193	-0,016	-0,138	-0,088	-0,126	0,025	-0,151	-0,030	0,370	0,077	0,252	-0,037	0,045	-0,002	0,147	-0,0
5-HETrE	0,014	-0,408	0,035	0,003	-0,092	-0,468	-0,557	-0,094	0,256	-0,198	0,002	-0,230	0,010	-0,248	0,297	-0,136	0,032	-0,
12-HEPE	-0,166	-0,060	0,091	0,121	0,021	0,024	-0,065	0,201	-0,314	-0,116	0,241	0,428	0,149	-0,068	-0,007	0,114	0,391	-0,2
15-HEPE	0,084	-0,270	0,075	0,118	0,028	-0,071	-0,183	0,160	-0,151	-0,013	0,184	0,179	0,046	-0,169	0,096	0,090	0,079	-0,*
18-HEPE	-0,003	-0,167	0,189	0,112	-0,059	0,038	0,031	0,144	-0,314	-0,017	0,351	0,295	0,079	-0,088	0,018	0,083	0,070	-0,0
7-HDPA	-0,028	-0,291	0,077	0,048	-0,076	-0,153	-0,270	0,027	-0,043	-0,189	0,323	0,065	0,140	-0,274	0,268	-0,094	0,190	-0,0
4-HDHA	-0,006	0,033	0,197	0,102	0,012	0,113	0,046	0,124	-0,111	0,007	0,462	0,263	0,108	-0,022	0,025	-0,005	0,294	-0,0
7-HDHA	-0,027	-0,339	0,091	0,168	-0,086	-0,196	-0,243	0,140	-0,066	-0,285	0,266	0,110	0,080	-0,310	0,259	-0,116	0,139	-0,'
5(S).6(R)- DiHETE	-0,014	-0,298	-0,037	0,095	-0,134	-0,139	-0,059	-0,005	-0,043	-0,322	0,232	0,101	0,262	-0,355	0,399	-0,266	0,027	0,1
(S).12(S)- DiHETE	-0,034	-0,216	0,092	0,197	0,033	0,016	-0,062	0,209	-0,223	-0,150	0,289	0,327	0,055	-0,171	0,075	-0,014	0,240	-0,0
(S).15(S)- DiHETE	-0,060	-0,138	0,044	0,164	0,039	0,025	0,009	0,182	-0,259	-0,198	0,302	0,340	0,081	-0,207	0,109	-0,031	0,199	-0,
14(15)- DiHET	-0,049	-0,086	0,084	0,131	0,087	0,026	-0,003	0,068	-0,234	-0,137	0,303	0,201	0,175	0,001	0,023	0,104	0,086	-0,
LXA4	-0,092	-0,128	0,051	0,154	0,136	0,061	-0,025	0,164	-0,245	-0,184	0,333	0,371	0,072	-0,130	0,072	0,006	0,228	-0,
PDX	-0,024	-0,132	0,129	0,233	-0,010	0,136	-0,039	0,228	-0,272	-0,057	0,310	0,364	0,118	-0,130	0,115	0,058	0,237	-0,
RvD4	-0,111	-0,083	0,090	0,249	0,124	0,054	-0,021	0,297	-0,227	-0,204	0,295	0,436	-0,024	-0,120	0,024	-0,003	0,195	-0,
RvD5	-0,044	-0,117	0,180	0,158	-0,025	0,059	0,014	0,244	-0,223	-0,101	0,325	0,340	0,014	-0,130	0,037	0,054	0,194	-0,0
RP, C- IONO,	reactive Monoc	e prote cytes; r lavag	in; ALT, NEU, I e	alanin Neutrop	e trans ohils; E	aminas EOS, (e; AST eosinop	, aspa phils; l	rtate tra _ymph,	ansamii Iympl	nase; L nocytes	DH, La; ; PLR	actate de , platel	ehydrog et to	jenase lympho	; Hb, H pcyte i	lemoglo ratio; l	obin BAL

 Negative correlation
 p < 0.05</th>
 p < 0.01</th>
 p < 0.001</th>
 p < 0.001</th>
 Positive correlation
 p < 0.05</th>
 p < 0.01</th>
 p < 0.001</th>

Figure 7. Correlation between bioactive lipids in the BALs of severe COVID-19 patients and

clinical parameters. Correlation tests were performed by using the non-parametric Spearman's rank using the Graphpad Prism Software. P<0.05 was the threshold of significance. Positive correlations are

shown using shades of green and negative correlation are shown using shades of red.